PLAT and lung carcinoma: Compared with gefitinib administration alone, the difference was statistically significant after gefitinib combined with ADI, indicating that ADI combined with gefitinib could inhibit the migration and invasion of gefitinib-resistant lung cancer cells by interfering with PLAT expression (Fig. 8C).